AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
286.04B
Market cap286.04B
Price-Earnings ratio
25.93
Price-Earnings ratio25.93
Dividend yield
1.73%
Dividend yield1.73%
Average volume
2.73M
Average volume2.73M
High today
$187.65
High today$187.65
Low today
$183.86
Low today$183.86
Open price
$186.89
Open price$186.89
Volume
1.61M
Volume1.61M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$153.41
52 Week low$153.41

Stock Snapshot

AstraZeneca(AZN) stock is priced at $182.88, giving the company a market capitalization of 286.04B. It carries a P/E multiple of 25.93 and pays a dividend yield of 1.73%.

On 2026-11-17, AstraZeneca(AZN) stock traded between a low of $183.86 and a high of $187.65. Shares are currently priced at $182.88, which is -0.5% above the low and -2.5% below the high.

AstraZeneca(AZN) shares are trading with a volume of 1.61M, against a daily average of 2.73M.

During the past year, AstraZeneca(AZN) stock moved between $153.41 at its lowest and $212.71 at its peak.

During the past year, AstraZeneca(AZN) stock moved between $153.41 at its lowest and $212.71 at its peak.

AZN News

TipRanks 10h
Clever Culture Systems Reports APAS Customer Growth and Market Expansion

LBT Innovations Limited ( (AU:CC5) ) has shared an announcement. Clever Culture Systems supplies APAS automated culture-plate reading technology for pharmaceut...

Zacks 17h
AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa - Zacks Investment Research

...

AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa - Zacks Investment Research
Benzinga 22h
AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europe

Regulators in the U.S. and European Union handed AstraZeneca Plc (NYSE:AZN) major regulatory wins across rare neuromuscular disease and oncology. The agencies...

AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europe

Analyst ratings

90%

of 10 ratings
Buy
90%
Hold
0%
Sell
10%

More AZN News

TipRanks 24h
AstraZeneca, Alexion announce Klygefa approved in EU

Alexion and AstraZeneca (AZN) Rare Disease’s Klygefa has been approved in the European Union, EU, as an add-on to standard therapy for the treatment of generali...

TipRanks 1d
FDA approves AstraZeneca’s Imfinzi regimen for cisplatin-ineligible MIBC

AstraZeneca ( (GB:AZN) ) has issued an announcement. The FDA approved AstraZeneca’s Imfinzi (durvalumab) with neoadjuvant enfortumab vedotin, followed by Imfin...

TipRanks 1d
Klygefa Approved in EU for Adults With Generalised Myasthenia Gravis

The latest update is out from AstraZeneca ( (GB:AZN) ). Alexion, AstraZeneca Rare Disease’s Klygefa has received EU approval as an add-on to standard therapy f...

Investor's Business Daily 2d
FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug

Summit Therapeutics said Sunday that the Food and Drug Administration didn't approve a China-developed drug to treat lung cancer, citing insufficient evidence t...

FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug
TipRanks 3d
AstraZeneca announces FDA approval of imfinzi/EV combination

AstraZeneca’s (AZN) imfinzi in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by imfinzi monotherapy as adjuvant treatment after ra...

Seeking Alpha 4d
AstraZeneca eliminates 600 respiratory and immunology sales reps: Bloomberg

AstraZeneca eliminates 600 respiratory and immunology sales reps: Bloomberg Nov 13, 2026, 2:51 PM ET AstraZeneca PLC (AZN) Stock By : Jonathan Block, SA News Ed...

AstraZeneca eliminates 600 respiratory and immunology sales reps: Bloomberg
TipRanks 4d
FDA approves AstraZeneca combo treatment for bladder cancer

The Food and Drug Administration said it approved AstraZeneca’s (AZN) Imfinzi in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.